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Introduction
Administration of a parenteral dose with microbial contamination may result in infective morbidity and death. Recent examples include: postoperative sepsis after inadequate aseptic handling of intravenous anaesthetic; loss of vision or further surgery due to endophthalmitis as a consequence of contaminated intravitreal injections in the USA; an outbreak of bloodstream infections requiring withdrawal of relevant stock due to contaminated intravenous analgesia in Taiwan; and deaths in newborns as a consequence of contaminated parenteral nutrition in France and the UK. [1] [2] [3] [4] This means it is important to implement safe procedures in routine practice to prevent inadvertent microbial dose contamination. For example, the risk of contamination is expected to be lower when procedures are undertaken in an environment with a low density of microbes than one with a high density. Therefore, it is often recommended to move aseptic preparation of parenteral doses away from a clinical environment (with a higher density of microbes) into a specially designed pharmaceutical environment [with a lower density of microbes (and particulates)]
in line with recognized standards operating in countries such as the USA or the UK. [5] [6] [7] For example, in the immediate area used to prepare parenteral medicines there could be more than 90 times the number of colony-forming units falling on to a 90 mm diameter trypticase soy agar plate in a 4 h period in a clinical environment than is allowed by the standards applied to pharmaceutical environments in some countries. 7, 8 The use of a pharmaceutical environment is particularly important in the preparation of batch doses, which carry the risk of contaminating multiple lots of individual doses, and where there is likely to be a period of storage before administration to patients. However, since pharmaceutical environments meeting recognized standards for aseptic dose preparation are costly and require operational expertise that may not always be readily available, they are not always used. Therefore, there is a need to balance the advantages and disadvantages of the procedures and the environments M A N U S C R I P T
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3 in which they are undertaken in order to obtain the desirable effects in routine clinical practice.
In 2009 we published a systematic review with meta-analysis to summarize published frequencies of contamination of parenteral doses prepared in clinical and pharmaceutical environments under aseptic techniques. 9 This provided some evidence favouring dose preparation in the pharmaceutical environment, but the conclusions were weakened by the small number of studies which were generally of low quality. It is possible that some earlier studies may have been missed because the initial review used only one database search engine (PubMed from 1947 onwards). Since our review, a considerable amount of new information has become available which needs to be incorporated into the analyses. In the meantime, clinical concern about methods to reduce morbidity and cost due to infections has been increasing. For example, an international initiative has sought to rationalize and harmonize standards for aseptic preparation of parenteral doses throughout Europe. 10, 11 It is clear that the existing evidence base needs to be reviewed, updated, and clarified by providing a more precise definition of the pharmaceutical environment. 9 Therefore, the aim of this study was to clarify and extend the evidence base to address the following three hypotheses: one, the risk of infective contamination is different for aseptic preparation in a clinical and pharmaceutical environment; two, the risk is also different for aseptic preparation of individual and batch doses within the same type of environment; and three, the risk is different for additives rather than no additives to sterile doses prior to administration. We also sought to consider future research needs in light of the current evidence base.
Methods
The literature search was undertaken on 10 February 2014 with a wider protocol than that undertaken by the previous review. 9 The present literature search used an additional search term, truncated search terms, and combination of three search terms only if more than 5000 results were returned for any two search term combination. Three databases were used for all available years: Medline from 1946 onwards using OvidSP; Embase from 1947 onwards using OvidSP; and the Cochrane Library. Attempts were made to identify further papers by hand searching.
The literature search included studies that involved microbial contamination with bacteria and/or fungi. The studies involved preparation of doses for parenteral administration to patients prepared under aseptic techniques, including simulation studies. Studies were excluded if they were not reported in the English language, if they only involved animals, or if they reported the rate of contamination of infusate stock (an infusate in a single container used to prepare multiple doses) rather than actual or simulated prepared doses (for example,
contamination of multi-dose vials after repeated use). Studies were also excluded if they involved the use of blood or a blood component, if there was freezing/thawing of prepared doses, or if there was reuse of equipment during dose preparation (except when used in the preparation of a single batch). For an environment to qualify as a pharmaceutical environment the recognized standard of the cabinet in which the doses were prepared and the room in which that cabinet was situated had to be specified in the record (journal article). When a single record reported more than one outcome, for example when using different preparation environments, each outcome was included as a separate study. Consistent data within the same record were combined only if whole groups of data could be combined.
The search terms (including variations and truncated terms) and number of results are shown in Table I . In brief, each of four search terms was combined with each of four further search terms, unless a combination returned more than 5000 results, in which case a third search term was added in an attempt to capture the most relevant results. It can be seen from Table I that a third search term was required on five occasions. Additional papers were sought through cross-referencing and discussion with experts in the field.
The literature search identified 42,246 records (17,662 from Medline, 20,824 from Embase and 3760 from the Cochrane Library) and 28,020 after duplicates had been removed.
The title and abstract (if necessary and accessible) of each of the 28,020 identified records was evaluated and excluded if it did not meet the above inclusion criteria. This left 137 records, which were individually subjected to a full text review to confirm relevance and compliance with the above criteria to yield a final total of 34 studies from 33 records. 8, Each of the final 19 studies from 17 records identified in our 2009 search were identified in the present search but five of those studies from four records were excluded due to inadequate and/or inadequately described pharmaceutical environments. 9, 12, [14] [15] [16] [18] [19] [20] [21] [22] 24, 33, 36, [43] [44] [45] [46] [47] The methodological stages of the search are shown in Figure 1 . As previously, the included studies were divided into groups according to whether doses were prepared in a clinical or pharmaceutical environment (hypothesis 1), whether doses had been prepared as individual
Two of the authors (P.D.A. and K.S.H.) independently assessed the quality of the included studies using the GRADE system with subsequent discussion to resolve any disagreement. 48, 49 The recommendations of the UK National Health Service Centre for
Reviews and Dissemination (CRD) and Cochrane as well as the PRISMA guidelines for reporting systematic reviews were considered at all stages during this review.
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Statistical analysis
The point estimate, standard error and 95% confidence interval for the contamination rate of each separate group was obtained by logarithmic (logit) transformation. When there was zero contamination in a group, a value of 0.5 contaminated doses was used to overcome the mathematical difficulties associated with logarithmic transformation (the log 10 of zero is minus infinity). Data amalgamation and the meta-analyses were undertaken using a random effects model and the software Comprehensive Meta Analysis version 2 (Biostat, Englewood, NJ, USA). One-group meta-analyses were used for hypotheses 1 and 2 and a two-group metaanalysis was used for hypothesis 3 due to the nature of the available studies. The random effects model was chosen because of the clinical heterogeneity of the studies, but the I 2 statistic is also presented. Comparisons between group means were undertaken using unpaired t-tests, with a two-tailed P < 0.05 considered statistically significant.
Results
Quality of studies
For the purpose of this review, both raters graded all of the included studies as low to very low quality, with three disagreements within these categories. After discussion, the majority of the studies were graded as low quality primarily because they were nonrandomized, and four studies were graded as very low quality primarily due to small sample size and limited procedural detail and high contamination rate. 18, 34, 36, 40 Overview of the rate of contamination of doses prepared in clinical and pharmaceutical environments A grand total of 16,552 doses eligible for inclusion were identified from 34 studies taken from 33 records, which are summarized in Table II . 8, The single record identified through other sources in our previous review was identified by the present literature search. 9, 12 M A N U S C R I P T 
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from seven studies (seven records 12, 17, 26, 34, [39] [40] [41] ) had been prepared in pharmaceutical environments. When all the data were combined, there was a significantly higher frequency of contamination of doses prepared in clinical than in pharmaceutical environments [2.5% (95% CI: 1.2, 5.5; n = 6383 doses) (I 2 = 95.69%; P < 0.001) vs 0.5% (95% CI: 0.1, 1.6; n = 6280 doses) (I 2 = 69.18%; P = 0.003); P = 0.044]. The between-study contamination was more variable in the clinical than in the pharmaceutical environment (range: 0.1-28.4% vs 0.0-2.6% respectively).
Doses sampled during or after administration
It was not possible to compare doses prepared in clinical and pharmaceutical environments that had been sampled during or after administration due to lack of data in the pharmaceutical environment.
Individual doses
All identified doses. 
Doses sampled without administration or prior to administration. There were 420
doses from five studies (five records 17, 27, 30, 37, 40 ) that had been sampled without administration or prior to administration, of which 252 doses from three studies (three records 27, 30, 37 ) had been prepared in clinical environments and 168 doses from two studies (two records 17, 40 ) had been prepared in pharmaceutical environments. When all the data were combined there was a non-significantly higher frequency of contamination of doses prepared in clinical than in pharmaceutical environments [2.3% (95% CI: 0.5, 10.1; N = 252 doses) (I 2 = 56.45%; P = 0.101) vs 2.1% (95% CI: 0.7, 5.8; N = 168 doses) (I 2 = 00.00%; P = 0.856); P = 0.923]. The between-study contamination was more variable in the clinical than in the pharmaceutical environment (range: 0.6-6.3% vs 2.0-2.6% respectively).
Doses sampled during or after administration. It was not possible to compare doses prepared in clinical and pharmaceutical environments that had been sampled during or after administration due to lack of data in the pharmaceutical environment. Doses sampled during or after administration. It was not possible to compare doses prepared as individual lots and as part of a batch that had been sampled during or after administration due to lack of data for doses prepared as part of a batch.
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Pharmaceutical environments
All identified doses. The analysis involved 6280 doses from seven studies (seven records 12, 17, 26, 34, [39] [40] [41] ). Of these, 168 doses from two studies (two records 17, 40 ) had been M A N U S C R I P T 
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ACCEPTED MANUSCRIPT 10 prepared as individual lots and 6112 doses from five studies (five records 12,26,34,39,41 ) had been
Hypothesis 3: undertaking additions to terminally sterilized doses
The maximum expected contamination rate of doses terminally sterilized according to appropriate and validated procedures is one per million.
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Clinical and pharmaceutical environments combined
It was not possible to combine doses from clinical and pharmaceutical environments, since no studies that reported the contamination rate of sterile doses with and without additives undertaken in pharmaceutical environments had been identified.
Clinical environments
The analysis involved 1723 doses from six studies (six records 15, 18, 21, 28, 29, 35 ). Of these, additions had been made to 1108 doses and no additions had been made to 615 doses. All of the doses had been prepared as individual lots and sampled during or after administration. Figure 3 shows the forest plot when all of the study data were combined in a meta-analysis.
There was a significantly higher frequency of contamination of doses with additives than without additives [risk ratio: 2.121 (95% CI: 1.093, 4.114); P = 0.026], with a low statistical heterogeneity (I 2 = 22.50%; P = 0.265).
Pharmaceutical environments
It was not possible to compare sterile doses with and without additives in pharmaceutical environments, since no relevant studies had been identified.
Discussion
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This update identified more than double the number of doses than the 2009 review, which we have attempted to summarize to help inform judgements when establishing policy and clinical practice that ultimately aim to reduce patient infection rates. 9 Overall, the contamination frequency was lower when doses had been prepared in pharmaceutical than in clinical environments, but reported rates were often unacceptably high in both settings. For example, the mean reported study frequency of microbial contamination of doses prepared under aseptic techniques in pharmaceutical environments could be >100 times higher than that expected from following the procedures recommended in Europe (>2.0% compared with 0.02%), and >2750 times higher in clinical environments than that expected in a pharmaceutical environment (>55.0% compared to 0.02%). 11 The greater number of studies identified in this update meant that a previously non-significant but intuitive finding of the previous review achieved statistical significance in the present review (Hypothesis 3).
9
Hypothesis 1: dose preparation in a clinical compared to a pharmaceutical environment
There was a consistently lower frequency of contamination of doses prepared in pharmaceutical environments compared to clinical environments. However, this finding was not found to be statistically significant for doses prepared as individual lots, despite up to more than a two-fold difference in the overall frequency of dose contamination (4.7% vs 2.1%
for all individual doses combined, and 2.3% vs 2.1% for only those individual doses sampled without administration or prior to administration). This lack of statistical significance could at least in part be explained by the limited data identified for doses prepared as individual lots in pharmaceutical environments (N = 168) (a potential type 2 error due to inadequate statistical power), which could have been compounded by necessary mathematical corrections during the analyses (see limitations below). A consistently narrower range of between-study frequencies of dose contamination was found for doses prepared in pharmaceutical than in clinical environments.
The lower frequency and variability of contamination of doses prepared in pharmaceutical than in clinical environments is intuitive since pharmaceutical facilities are constructed and operated to restrict the number of environmental microbes, incorporate specialized equipment operated by staff wearing special clothing to minimize shedding of micro-organisms (and particles) and who have more consistent and extensive training in the validation in the use of aseptic techniques. 8 When reported, the types of micro-organisms found after preparation in pharmaceutical environments were generally of low pathogenicity.
The same bacteria were reported in doses prepared in clinical environments, but a wider range of micro-organisms was found in this setting, including various Gram-negative bacteria and fungi that have greater pathogenic potential. Not only are limited or no environmental control M A N U S C R I P T
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procedures followed in clinical environments, but the closer proximity of drug preparation to patients serves as an additional source of micro-organisms that are antibiotic resistant and/or more pathogenic. Indeed, perceived benefits of pharmaceutical rather than clinical environments for aseptic preparation of parenteral doses have been noted in national documents, such as in the UK, and particularly for high-risk products such as parenteral nutrition.
54-56
In addition to potential clinical benefits it is also necessary to consider the economic consequences of where doses are prepared. None of the reviewed studies undertook a costeffectiveness analysis but the start-up costs for building a new facility to create an appropriate pharmaceutical environment would be high (e.g. several million national currency units in Europe or the USA). There are also substantial ongoing costs (including operator training, maintenance, monitoring for environmental contaminants, and the need for an appropriately qualified manager). In addition, logistic issues created by a centralized facility, such as the need to reallocate staff resource from wards to the pharmacy department, and the need to safely and efficiently deliver drugs to points of use, would have to be addressed.
Hypothesis 2: dose preparation as individual lots or as part of a batch
For all the doses in both clinical and pharmaceutical environments combined, contamination was found to be higher in doses prepared as individual lots rather than as part of a batch. This difference was found to be significant in pharmaceutical environments but not in clinical environments. It is intuitive that individual doses would be a higher risk than batch doses in pharmaceutical environments since the risks of batch preparation are offset by fewer environmental contaminants, less variable techniques, and the availability of specialized equipment. It is also intuitive that potential benefits of batch preparation would be lost in an uncontrolled environment with greater contaminants where more variable techniques are employed and no specialized equipment for batch production is available. These findings support recommendations to limit the expiry of parenteral doses prepared under aseptic techniques in clinical environments, for example to 24 h in the UK, which effectively preclude batch preparation, and which do not apply to pharmaceutical environments (although different additional requirements do apply).
56
Hypothesis 3: the effect of undertaking additions to terminally sterilized doses
It is reasonable to suggest that aseptic manipulations to a sterile dose can only increase the risk of microbial contamination, but there is limited evidence for such an effect. Unlike the 2009 review, which reported no significant effect of additions to sterilized doses, this updated review found a significantly higher contamination rate of sterile doses subjected to additions compared to those that were not [a risk ratio of 1.459 (P = 0.682) and 2.121 (P = M A N U S C R I P T
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13 0.026) respectively]. 9 This difference can be explained by use of a meta-analysis based on only three studies with high statistical heterogeneity (I 2 = 66.45%, P = 0.055) in the 2009 review, and a meta-analysis based on six studies with lower heterogeneity (I 2 = 22.50%, P = 0.265) in the present review. 9, 15, 18, 21, 28, 29, 35 This finding is consistent with the intuitive idea that aseptic manipulations should be minimized in uncontrolled environments such as hospital wards whenever possible. Nevertheless, adequate protocols and training are still required when it is necessary to prepare doses in clinical environments under aseptic technique. The updated conclusion that additions to sterile doses in clinical environments increase the contamination rate is in line with the findings for the previous two hypotheses.
Limitations
The evidence base was limited and generally based on poor quality studies, weakening the conclusions of this paper. One of the main limitations is that the studies did not primarily set out to examine the hypotheses raised in this review and so did not use the most appropriate study designs to address the hypotheses raised in this review. Furthermore, although there are substantially more studies in the current review than in the 2009 review, 9 there is still the possibility that a type 2 error may have arisen when testing specific hypotheses. For example, there were only 168 individual doses prepared in pharmaceutical environments identified. The risk of type 2 error may have also been increased by the need to add 0.5 contaminated doses in a group when it in reality there were no contaminated doses. For example, the effect on the rate of contamination of doses prepared as individual lots in a pharmaceutical environment in one study was reported as 0.0% (zero contaminated doses from a total of 18 doses) but was included in the analyses as 2.4% (0.5 contaminated doses from a total of 18 doses). 40 The relevance of this mathematical complication is reduced as the sample size increases. Another potential limitation is that the studies spanned a period of >40 years (1972 to 2013), most of which were more than 10 years old [79% (27 from 34 studies)], which raises the possibility that the overall results do not exactly reflect current practice with currently used products.
Finally, the general lack of head-to-head trials (seven from a total of 33 records) has meant that in some cases less robust analyses had to be used. In standard meta-analyses involving head-to-head trials, the differences between two groups of individual studies are established and amalgamated (two group meta-analysis). By contrast, in the present work for hypotheses 1 and 2 the average results from studies involving each group were amalgamated separately (one group meta-analysis) and then compared with each other. This increases the risk of bias since the products tested and conditions in the two comparator groups are less well matched. The data reported from the containers rather than from the associated giving sets.
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n The data from sample 2 of group I have been excluded since they represented the same doses, and data from group II have been excluded due to unacceptable conditions. p Study design excluded patients receiving electrolytes, antibiotics or cancer chemotherapy.
q Data reported from cases without reuse of administration sets.
r Data from sampling immediately after dose preparation, not those same doses sampled after infusion (when three contaminated samples were identified). 
Favours additives Favours no additives
